Developer docs
API playgroundTry for free, no card

Search company profiles

Dopavision

Full company profile

uuid00057s3

Namestring
Dopavision
Legal namestring
Dopavision GmbH
Websiteurl
dopavision.com
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

Dopavision is a Berlin-based clinical-stage digital therapeutics company developing MyopiaX®, a smartphone- and VR-based digital therapeutic that uses selective ocular light stimulation to slow myopia progression in children and adolescents.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, myopia control, ophthalmic medical devices, light-based therapy, pediatric eye care
Industry3 codes
PRIMARYHLAKAKAK
Contact Lens Specialty & Myopia Control
SECONDARYHLAKAKAM
Vision Therapy & Orthoptics
SECONDARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Ophthalmic Goods3851
Product category
Digital Therapeutics for Pediatric Myopia
No data
Revenue model1 record
1Digital Therapeutic Product (MyopiaX)
TypeSubscription Recurring
Description

The company is developing a prescription digital therapeutic for childhood myopia control. Revenue model not yet publicly disclosed as product is still in clinical trial stage.

dopavision.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1MyopiaX®
Description

Lead product - a smartphone application that administers selective ocular light stimulation via VR headset to slow myopia progression in children. It delivers therapeutic intervention while children play games or use educational digital content.

dopavision.com
Core offering1 text field

Dopavision develops MyopiaX®, a smartphone-based prescription digital therapeutic that delivers patented selective ocular light stimulation through a VR headset and Bluetooth controller to slow the progression of myopia in children aged 6–14. The product is administered as twice-daily gamified VR sessions targeting melanopsin-mediated dopamine pathways in the retina, and is currently being evaluated as a regulated medical device in the MyopiaX-1 clinical trial (NCT04967287) across Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • MyopiaX treatment group showed 0.14 mm axial length change and -0.19 D spherical equivalent refraction at 6 months in MyopiaX-1 trial (n=50)
Product overview1 text field

Dopavision is a digital therapeutics company offering MyopiaX®, a single core product consisting of a smartphone application that delivers selective ocular light stimulation through consumer electronics (VR headset and Bluetooth controller). MyopiaX® is designed as an interactive, game-based therapeutic where children use the app twice daily to receive light-based treatment targeting the dopamine pathway to slow myopia progression. The product is under clinical investigation (MyopiaX-1 trial NCT04967287) and is being developed as a medical device meeting EN 62304 and ISO 14971 standards.

Product and service1 record
1MyopiaX®
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Digital health ecosystem partner providing access to healthcare system and industry network. Flying Health co-founders Markus Müschenich and Christian Lautner were founding investors.

2Centre for Eye Research Ireland (Technological University Dublin)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Coordinating center for MyopiaX-1 clinical trial led by Prof. Ian Flitcroft and Prof. James Loughman. Provides clinical research expertise in ophthalmology.

dopavision.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Pure-play prescription digital therapeutics company (FDA-cleared EndeavorRx for pediatric ADHD). Directly comparable in regulatory model (prescription digital therapeutic with gamified UI on consumer devices) and in commercial challenges of provider reimbursement, distribution and adherence.

2Pear Therapeutics
TypeOthers
Description

Pioneer of FDA-authorized prescription digital therapeutics (reSET, reSET-O) for substance use disorder and opioid use disorder. Historically the closest comparable pure-play digital therapeutics company; its 2023 bankruptcy and asset sale illustrate the commercial and reimbursement risks inherent to the category Dopavision is entering.

TypeBroad incumbent
Description

Large ophthalmology and vision-care incumbent with a myopia management portfolio (contact lenses, orthokeratology lens designs, and partnerships). Competes for the same optometry/ophthalmology channel and pediatric myopia patient population.

TypeDirect peer
Description

Digital therapeutic company that received FDA De Novo authorization for a VR-based pediatric ophthalmology treatment (amblyopia). Directly comparable in regulatory pathway (Rx digital therapeutic, novel pediatric device, novel modality) and in integrating VR hardware with a clinical-grade software therapeutic in ophthalmology.

TypeBroad incumbent
Description

Spectacle lens giant whose MiYOSMART lenses incorporate patented D.I.M.S. (Defocus Incorporated Multiple Segments) technology for myopia control. Alternative non-invasive pediatric myopia intervention competing for the same optometry/ophthalmology prescribing channel.

TypeBroad incumbent
Description

Global contact lens manufacturer whose MiSight 1 day is the first FDA-approved soft contact lens for myopia control in children. Competes for the same prescribing eye-care professional and the same pediatric myopia patient, but via an optical/pharmaceutical-adjacent device rather than a digital therapeutic.

TypeDirect peer
Description

Australian medtech company marketing a CE-marked repeated low-level red light (RLRL) therapy device for childhood myopia control. Direct competitor to MyopiaX — same disease (pediatric myopia), same intervention concept (light-based), different light modality and hardware form factor.

TypeBroad incumbent
Description

Global lens incumbent whose Stellest spectacle lenses (Highly Aspherical Lenslets) target myopia progression in children and are sold through ophthalmology and optometry practices. Competes for the same patient and prescriber channel with a non-digital modality.

TypeBroad incumbent
Description

Joint venture (now under CooperVision) developing Diffusion Optics Technology (DOT) spectacle lenses for slowing myopia progression. Comparable in targeting pediatric myopia control through an eye-care professional prescription channel.

TypeBroad incumbent
Description

Global ophthalmology incumbent (Lucentis, Beovu, Xiidra) and a Dopavision Series A investor. Highly relevant as a comparable end-stage commercializer of an ophthalmology product franchise and as the most likely strategic acquirer/partner given existing investor relationships and former-employees on the team.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dopavision

Digital Therapeutics for Pediatric Myopiadopavision.com

Dopavision is a Berlin-based clinical-stage digital therapeutics company developing MyopiaX®, a smartphone- and VR-based digital therapeutic that uses selective ocular light stimulation to slow myopia progression in children and adolescents.

Dopavision firmographics

Firmographics
Name
Dopavision
Legal name
Dopavision GmbH
Website
https://dopavision.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Dopavision is a Berlin-based clinical-stage digital therapeutics company developing MyopiaX®, a smartphone- and VR-based digital therapeutic that uses selective ocular light stimulation to slow myopia progression in children and adolescents.
Ownership category
akta.pro rank

Dopavision industry classification

Industry
Product category
Digital Therapeutics for Pediatric Myopia
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Ophthalmic Goods Manufacturing (339115)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAKAKAK
Contact Lens Specialty & Myopia Control
SECONDARYHLAKAKAM
Vision Therapy & Orthoptics
SECONDARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Digital therapeutics
  • Myopia control
  • Ophthalmic medical devices
  • Light-based therapy
  • Pediatric eye care

Where Dopavision is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Dopavision business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Digital Therapeutic Product (MyopiaX): The company is developing a prescription digital therapeutic for childhood myopia control. Revenue model not yet publicly disclosed as product is still in clinical trial stage.

Distribution channels2 records

Marketing channels3 records

Dopavision product offering

Product offering

Core offering

Dopavision develops MyopiaX®, a smartphone-based prescription digital therapeutic that delivers patented selective ocular light stimulation through a VR headset and Bluetooth controller to slow the progression of myopia in children aged 6–14. The product is administered as twice-daily gamified VR sessions targeting melanopsin-mediated dopamine pathways in the retina, and is currently being evaluated as a regulated medical device in the MyopiaX-1 clinical trial (NCT04967287) across Europe.

Product overview

Dopavision is a digital therapeutics company offering MyopiaX®, a single core product consisting of a smartphone application that delivers selective ocular light stimulation through consumer electronics (VR headset and Bluetooth controller). MyopiaX® is designed as an interactive, game-based therapeutic where children use the app twice daily to receive light-based treatment targeting the dopamine pathway to slow myopia progression. The product is under clinical investigation (MyopiaX-1 trial NCT04967287) and is being developed as a medical device meeting EN 62304 and ISO 14971 standards.

Differentiator

Problem solved

Functional benefit

Brands

  • MyopiaX®: Lead product - a smartphone application that administers selective ocular light stimulation via VR headset to slow myopia progression in children. It delivers therapeutic intervention while children play games or use educational digital content.

Products and services

  • MyopiaX®

Quantifiable outcome

  • MyopiaX treatment group showed 0.14 mm axial length change and -0.19 D spherical equivalent refraction at 6 months in MyopiaX-1 trial (n=50)

Companies that use Dopavision

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Dopavision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Dopavision partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Flying HealthminorStrategic or Co-development PartnerDigital health ecosystem partner providing access to healthcare system and industry network. Flying Health co-founders Markus Müschenich and Christian Lautner were founding investors.
  • Centre for Eye Research Ireland (Technological University Dublin)coreStrategic or Co-development PartnerCoordinating center for MyopiaX-1 clinical trial led by Prof. Ian Flitcroft and Prof. James Loughman. Provides clinical research expertise in ophthalmology.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Dopavision competitors and assessment

Company assessment

Emerging players

  • Akili Interactive: Pure-play prescription digital therapeutics company (FDA-cleared EndeavorRx for pediatric ADHD). Directly comparable in regulatory model (prescription digital therapeutic with gamified UI on consumer devices) and in commercial challenges of provider reimbursement, distribution and adherence.

Others

  • Pear Therapeutics: Pioneer of FDA-authorized prescription digital therapeutics (reSET, reSET-O) for substance use disorder and opioid use disorder. Historically the closest comparable pure-play digital therapeutics company; its 2023 bankruptcy and asset sale illustrate the commercial and reimbursement risks inherent to the category Dopavision is entering.

Broad incumbents

  • Bausch + Lomb: Large ophthalmology and vision-care incumbent with a myopia management portfolio (contact lenses, orthokeratology lens designs, and partnerships). Competes for the same optometry/ophthalmology channel and pediatric myopia patient population.
  • Hoya Vision Care (MiYOSMART): Spectacle lens giant whose MiYOSMART lenses incorporate patented D.I.M.S. (Defocus Incorporated Multiple Segments) technology for myopia control. Alternative non-invasive pediatric myopia intervention competing for the same optometry/ophthalmology prescribing channel.
  • CooperVision (MiSight): Global contact lens manufacturer whose MiSight 1 day is the first FDA-approved soft contact lens for myopia control in children. Competes for the same prescribing eye-care professional and the same pediatric myopia patient, but via an optical/pharmaceutical-adjacent device rather than a digital therapeutic.
  • EssilorLuxottica (Stellest): Global lens incumbent whose Stellest spectacle lenses (Highly Aspherical Lenslets) target myopia progression in children and are sold through ophthalmology and optometry practices. Competes for the same patient and prescriber channel with a non-digital modality.
  • SightGlass Vision: Joint venture (now under CooperVision) developing Diffusion Optics Technology (DOT) spectacle lenses for slowing myopia progression. Comparable in targeting pediatric myopia control through an eye-care professional prescription channel.
  • Novartis Pharmaceuticals: Global ophthalmology incumbent (Lucentis, Beovu, Xiidra) and a Dopavision Series A investor. Highly relevant as a comparable end-stage commercializer of an ophthalmology product franchise and as the most likely strategic acquirer/partner given existing investor relationships and former-employees on the team.

Direct peers

  • Luminopia: Digital therapeutic company that received FDA De Novo authorization for a VR-based pediatric ophthalmology treatment (amblyopia). Directly comparable in regulatory pathway (Rx digital therapeutic, novel pediatric device, novel modality) and in integrating VR hardware with a clinical-grade software therapeutic in ophthalmology.
  • Eyerising International: Australian medtech company marketing a CE-marked repeated low-level red light (RLRL) therapy device for childhood myopia control. Direct competitor to MyopiaX — same disease (pediatric myopia), same intervention concept (light-based), different light modality and hardware form factor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Dopavision compliance and trust

Trust signal

Compliance1 record

Dopavision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dopavision leadership team

Management profile

Number of profiles

Profiles11 records

Dopavision funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dopavision M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dopavision

What does Dopavision do?

Dopavision develops MyopiaX®, a smartphone-based prescription digital therapeutic that delivers patented selective ocular light stimulation through a VR headset and Bluetooth controller to slow the progression of myopia in children aged 6–14. The product is administered as twice-daily gamified VR sessions targeting melanopsin-mediated dopamine pathways in the retina, and is currently being evaluated as a regulated medical device in the MyopiaX-1 clinical trial (NCT04967287) across Europe.

Is Dopavision a public or private company?

Dopavision is a private company. It is classified as venture growth investor backed and is currently operating.

When was Dopavision founded?

Dopavision was founded in 2017. It employs 1 to 10 people.

Where is Dopavision based?

Dopavision is headquartered in Berlin, Germany, in the Europe region.

How does Dopavision make money?

One revenue line is on record: digital Therapeutic Product (MyopiaX).

Who are Dopavision's main competitors?

Akili Interactive is listed as an emerging player. Pear Therapeutics is listed as an others. Broad incumbents are Bausch + Lomb, Hoya Vision Care (MiYOSMART), CooperVision (MiSight), EssilorLuxottica (Stellest), SightGlass Vision and Novartis Pharmaceuticals. Direct peers are Luminopia and Eyerising International.

Does Dopavision have an API?

No public API is recorded for Dopavision.

What industry is Dopavision in?

Dopavision's product category is Digital Therapeutics for Pediatric Myopia. Its primary akta.pro industry code is HLAKAKAK, Contact Lens Specialty & Myopia Control, with a secondary code of HLAKAKAM, Vision Therapy & Orthoptics. Its NAICS code is 334510 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MedicalstartupsTop 8 Myopia Treatment startups 2025The article presents a curated list of eight startups and companies involved in myopia treatment technologies, including AI diagnostics, digital therapeutics, and specialized contact lenses. It provides details on the specific focus areas and funding status for entities such as Mediwhale, Dopavision, and Myoptechs.Business Wire BlogDopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive MyopiaDopavision announced topline results from its MyopiaX-1 trial, a six-month randomized controlled study of 124 myopic children across six European countries. The trial found MyopiaX safe and tolerable with no ocular safety events and signals of clinical effect on myopia progression. The trial is scheduled to complete in September 2024.GlobeNewswireDopavision Reports Successful Completion of Enrollment for MyopiaX-1 TrialDopavision completed enrollment in its MyopiaX-1 trial, a randomized, active-controlled study of MyopiaX® in pediatric myopia. The 12-month trial, conducted at 10 sites across five countries, is expected to yield first clinical results in Q1 2024, with completion planned for September 2024.GlobeNewswireDopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are ActiveDopavision announced that all MyopiaX-1 trial sites in Germany, Spain, the Netherlands, and the UK are active, with enrollment ongoing. The randomized, active-controlled trial evaluates MyopiaX, a light-based therapy targeting the dopamine pathway in children with progressive myopia. First results are expected in early 2024.BusinessCloudBillionaire invests in startup trials companyPeter Thiel invested in London-based Lindus Health, a startup that delivers end-to-end clinical trials for healthtech and biotech. The company has raised £5m from investors, including Thiel, and is running trials for conditions like tinnitus and insomnia. It is also partnering with Pharmanovia, Oto, and Dopavision for further trials.GlobeNewswireDopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific OfficerDopavision appointed Prof. Dr. Jens Ellrich as Chief Scientific Officer to lead research on its myopia control digital therapeutic MyopiaX. The first-in-human clinical investigation of MyopiaX is ongoing across Europe. Ellrich brings over 85 peer-reviewed papers and prior executive roles in digital therapeutics.GlobeNewswireDopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory BoardDopavision appointed Dr. Dirk Sauer, former head of Novartis' ophthalmology development unit, as chair of its advisory board. The appointment aims to advance MyopiaX, a digital therapeutic for childhood myopia, which is in clinical trials in Germany, Portugal, Spain, and Ireland.GlobeNewswireDopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive OfficerDopavision appointed Mark S. Wuttke, Ph.D., as CEO, succeeding Stefan Zundel, who remains on the advisory board. Wuttke brings 12 years at Novartis in ophthalmology. The company's MyopiaX digital therapeutic for childhood myopia is in clinical trials in Europe.FinSMEsDopavision Raises €12M in Series A FundingBerlin-based digital therapeutics company Dopavision has raised €12 million in Series A funding led by Seventure Partners, with participation from Novartis Pharmaceuticals and Boehringer Ingelheim Venture Fund. The company plans to utilize these funds for the clinical development of its lead product, MyopiaX, which targets childhood myopia through digital gaming interventions.GlobeNewswireDopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical TrialsDopavision closed a €12 million Series A round led by Seventure Partners with Novartis Pharmaceuticals joining as investors. The funds will advance MyopiaX, a digital therapeutic for childhood myopia, through clinical trials. The company aims to halt myopia progression and prevent sight-threatening conditions.